Company Number: 14848305

Analysis Date: 2025-07-29 17:43 UTC

Financial Health Assessment for TUPEL RESEARCH LTD

---

1. Financial Health Score: A

Explanation:
TUPEL RESEARCH LTD shows a strong financial position for a newly incorporated micro-entity. With positive net current assets and net assets of £833,988, the company demonstrates solid liquidity and equity for its scale and age. The absence of liabilities beyond current creditors and a clean balance sheet further supports an excellent financial standing. The company’s financial "vitals" reveal healthy cash reserves relative to short-term obligations, indicating no immediate distress or solvency concerns.

---

2. Key Vital Signs

Metric	Value	Interpretation
Current Assets	£1,156,845	Strong cash and short-term asset base
Current Liabilities	£322,857	Manageable short-term obligations
Net Current Assets	£833,988	Positive working capital, good liquidity
Net Assets (Equity)	£833,988	Solid capital base, no long-term debt
Number of Employees	1	Lean operation, low overhead
Account Category	Micro	Simplified filing, typical for early-stage
Company Age	1 year	Early development phase, growth potential

Interpretation:

• Healthy cash flow reserve: The company holds nearly four times the current liabilities in current assets, akin to a patient with a strong pulse and stable vital signs, indicating it can comfortably meet short-term debts.
• Low leverage: No indication of long-term debt or financial strain, reducing risk of distress symptoms.
• Lean staffing: With only one employee, overheads are minimal, which is typical and often beneficial for early-stage research companies.
• Micro-entity status: Simplified regulatory and reporting requirements reduce administrative burden, allowing focus on growth and innovation.

---

3. Diagnosis

TUPEL RESEARCH LTD exhibits the financial profile of a well-capitalized, early-stage research entity. The "symptoms" of its financial health include strong liquidity, no indication of distress or excessive liabilities, and a robust equity base, which is crucial for sustaining operations and funding research development activities. The company’s balance sheet is "healthy," with no red flags such as negative working capital or accumulated losses.

The director and majority shareholder’s scientific background aligns with the company’s SIC code in research and experimental development, suggesting operational coherence. The absence of overdue filings or penalty risks further supports administrative health.

However, as a young micro-entity, the company should be mindful that growth and scaling often introduce complexities, including increased liabilities and operational costs, which require careful financial management.

---

4. Recommendations

To maintain and enhance financial wellness, consider the following:

• Cash Flow Monitoring:
  Regularly track cash inflows and outflows to ensure liquidity remains robust as operations expand. Early detection of cash flow "symptoms" like tightness will enable proactive management.

• Operational Scaling Plan:
  As research progresses, prepare for potential increases in staff and expenditure. Develop budgets and financial forecasts to anticipate working capital needs.

• Diversify Funding Sources:
  Explore grants, research funding, or equity investment to strengthen capital reserves and reduce dependency on founder funding.

• Maintain Compliance Discipline:
  Continue timely filing of accounts and confirmation statements to avoid penalties and maintain corporate reputation.

• Risk Management:
  Assess potential financial risks, including market, operational, and regulatory factors, and consider appropriate mitigation strategies.

---